@article {DAMASKOS3129, author = {CHRISTOS DAMASKOS and THEODORE KARATZAS and LAMPROS NIKOLIDAKIS and IOANNIS D. KOSTAKIS and STEFANOS KARAMAROUDIS and GEORGIOS BOUTSIKOS and ZOI DAMASKOU and ALKIVIADIS KOSTAKIS and GREGORY KOURAKLIS}, title = {Histone Deacetylase (HDAC) Inhibitors: Current Evidence for Therapeutic Activities in Pancreatic Cancer}, volume = {35}, number = {6}, pages = {3129--3135}, year = {2015}, publisher = {International Institute of Anticancer Research}, abstract = {Pancreatic carcinoma is one of the leading causes of cancer death. Current standard treatments include surgical resection, chemotherapy and radiotherapy but patient{\textquoteright}s prognosis remains poor and present severe side-effects. Contemporary oncology found a wide variety of novel anticancer drugs that regulate the epigenetic mechanisms of tumor genesis. Histone deacetylases (HDACs) are enzymes with pleiotropic activities that control critical functions of the cell through regulation of the acetylation states of histone proteins and other non-histone protein targets. They are divided into four groups, each with different localization in the cell, role and structure. Histone deacetylase inhibitors (HDACIs) are substances, which inhibit the function of HDACs. We recognize four leading groups (hydroxamic acid, cyclic tetrapeptide, benzamide, aliphatic acid). There are many HDACIs currently in pre-clinical and two (vorinostat, romidepsin) in clinical stages of investigation for pancreatic cancer. Numerous studies argue for the use HDACIs as monotherapy, others suggest that combination of HDACIs with other antitumor drugs has better therapeutic results. This review focuses on the use of HDACIs as novel anticancer drugs and will explain the mechanisms of therapeutic effect on pancreatic cancer.}, issn = {0250-7005}, URL = {https://ar.iiarjournals.org/content/35/6/3129}, eprint = {https://ar.iiarjournals.org/content/35/6/3129.full.pdf}, journal = {Anticancer Research} }